Home › Companies › Y-mAbs Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Y-mAbs Therapeutics, Inc.’s Form 8-K, filed 2025-07-15 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024 2025-2026
Explore Y-mAbs Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Y-mAbs Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-07-15 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: David N. Gill | 18,926,572 | -- | -- | 11,924,775 | 3,133,377 | Majority: yes |
| Proposal 2: Ratification of the Appointment of the Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 2 | 32,884,437 | 1,097,151 | 3,136 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on the Compensation of the Named Executive Officers The Company's stockholders approved Proposal 3 | 27,011,027 | 3,838,565 | 1,755 | -- | 3,133,377 | Majority: yes |
Source: Y-mAbs Therapeutics, Inc., Form 8-K, filed with the SEC on 2025-07-15 — read the filing on EDGAR.
Each item below shows how the 126 asset managers that disclosed a Y-mAbs Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Y-mAbs Therapeutics, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of the Named Executive Officers The Company's stockholders approved Proposal 3”): 27,011,027 for, 3,838,565 against, per its Form 8-K filed 2025-07-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,882,638 outstanding shares: 62% for, 9% against (70% of the company cast a for/against vote).
The 126 asset managers below cast 98% of the shares they voted on this item FOR (20,777,596 for, 325,910 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 4,031,230 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 3,012,000 | 0 | 0 | 0 | For |
| BlackRock | 2,434,042 | 0 | 0 | 0 | For |
| Caligan Partners LP | 2,292,049 | 0 | 0 | 0 | For |
| Vanguard | 1,977,583 | 0 | 0 | 0 | For |
| BOOTHBAY FUND MANAGEMENT, LLC | 643,133 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 590,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 583,723 | 0 | 0 | 0 | For |
| Charles Schwab | 558,372 | 0 | 0 | 0 | For |
| Fidelity | 547,006 | 0 | 0 | 0 | For |
| State Street | 532,036 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 325,000 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 323,618 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 300,000 | 0 | 0 | 0 | For |
| Dimensional | 0 | 283,796 | 0 | 0 | Against |
| DE Shaw | 275,747 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 234,722 | 0 | 0 | 0 | For |
| Federated Hermes | 210,397 | 0 | 0 | 0 | For |
| Northern Trust | 186,944 | 0 | 0 | 0 | For |
| Two Sigma | 184,237 | 0 | 0 | 0 | For |
| Citadel | 173,950 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 114,329 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 112,268 | 0 | 0 | 0 | For |
| Goldman Sachs | 102,464 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 97,864 | 0 | 0 | 0 | For |
Showing the 25 largest of 126 asset managers. See all 126 in the interactive database.
Combines 3 wordings of this item as funds reported it.
61% Majority: yes · of votes cast
Y-mAbs Therapeutics, Inc.’s own tally for this item (“Elect Director: David N. Gill”): 18,926,572 for, 11,924,775 withheld, per its Form 8-K filed 2025-07-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,882,638 outstanding shares: 43% for, 27% withheld (70% of the company cast a for/withheld vote).
The 48 asset managers below cast 100% of the shares they voted on this item FOR (4,263,209 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,882,029 | 0 | 0 | 0 | For |
| BlackRock | 1,331,865 | 0 | 0 | 0 | For |
| Fidelity | 517,346 | 0 | 0 | 0 | For |
| Charles Schwab | 279,183 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 234,022 | 0 | Abstain |
| Federated Hermes | 101,334 | 0 | 0 | 0 | For |
| Equitable | 46,936 | 0 | 34,620 | 0 | For |
| Goldman Sachs | 0 | 0 | 55,809 | 0 | Abstain |
| TIAA | 50,320 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 42,025 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 31,990 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 28,854 | 0 | Abstain |
| Northern Trust | 0 | 0 | 27,419 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 26,265 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 24,900 | 0 | Abstain |
| Global X | 0 | 0 | 20,117 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 18,654 | 0 | Abstain |
| PACE SELECT ADVISORS TRUST | 0 | 0 | 17,100 | 0 | Abstain |
| HC CAPITAL TRUST | 0 | 0 | 14,136 | 0 | Abstain |
| CLEARWATER INVESTMENT TRUST | 0 | 0 | 13,239 | 0 | Abstain |
| Brighthouse | 0 | 0 | 12,799 | 0 | Abstain |
| John Hancock | 0 | 0 | 12,203 | 0 | Abstain |
| Pacific Life | 11,982 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 10,211 | 0 | Abstain |
| ProShares | 0 | 0 | 8,587 | 0 | Abstain |
Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.
Combines 2 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Y-mAbs Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of the Appointment of the Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 2”): 32,884,437 for, 1,097,151 against, per its Form 8-K filed 2025-07-15 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 43,882,638 outstanding shares: 75% for, 3% against (77% of the company cast a for/against vote).
The 47 asset managers below cast 100% of the shares they voted on this item FOR (4,903,833 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,882,029 | 0 | 0 | 0 | For |
| BlackRock | 1,331,865 | 0 | 0 | 0 | For |
| Fidelity | 517,346 | 0 | 0 | 0 | For |
| Charles Schwab | 279,183 | 0 | 0 | 0 | For |
| Dimensional | 234,022 | 0 | 0 | 0 | For |
| Federated Hermes | 101,334 | 0 | 0 | 0 | For |
| Equitable | 81,556 | 0 | 0 | 0 | For |
| Goldman Sachs | 55,809 | 0 | 0 | 0 | For |
| TIAA | 50,320 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 42,025 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 31,990 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,854 | 0 | 0 | 0 | For |
| Northern Trust | 27,419 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 26,265 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 24,900 | 0 | 0 | 0 | For |
| Global X | 20,117 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 18,654 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 17,100 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 13,239 | 0 | 0 | 0 | For |
| Brighthouse | 12,799 | 0 | 0 | 0 | For |
| John Hancock | 12,203 | 0 | 0 | 0 | For |
| Pacific Life | 11,982 | 0 | 0 | 0 | For |
| Voya | 10,211 | 0 | 0 | 0 | For |
| ProShares | 8,587 | 0 | 0 | 0 | For |
| Jackson National | 8,406 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.
Ranked by the number of Y-mAbs Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 43,882,638 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Paradigm Biocapital Advisors LP | 9.19% |
| 2 | Polar Capital Holdings Plc | 6.86% |
| 3 | BlackRock | 5.55% |
| 4 | Caligan Partners LP | 5.22% |
| 5 | Vanguard | 4.51% |
| 6 | BOOTHBAY FUND MANAGEMENT, LLC | 1.47% |
| 7 | Sofinnova Investments, Inc. | 1.34% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.33% |
| 9 | Charles Schwab | 1.27% |
| 10 | Fidelity | 1.25% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Johan Wedell‑Wedellsborg | 10.75% | DEF14A |
| Dr. James I. Healy | 5.27% | DEF14A |
| Thomas Gad | 3.05% | DEF14A |
| Michael Rossi | 0.77% | DEF14A |
| Dr. Ashutosh Tyagi | 0.27% | DEF14A |
| David N. Gill | 0.26% | DEF14A |
| Laura J. Hamill | 0.20% | DEF14A |
| Peter Pfreundschuh | 0.13% | DEF14A |
| Dr. Mary Tagliaferri | 0.07% | DEF14A |
Percentages above are of 43,882,638 shares outstanding, as reported by Y-mAbs Therapeutics, Inc. on its Form 10-Q dated 2024-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Y-mAbs Therapeutics, Inc.’s 10-Q dated 2024-04-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Y-mAbs Therapeutics, Inc.'s shareholder meeting held 2025-07-11, in the 2025-2026 proxy season, 126 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 487 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY VOTE BASIS, THE COMPENSATION OF THE COMPANY'S NAMED… — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Y-mAbs Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-07-15.
Y-mAbs Therapeutics, Inc. proxy season coverage: 2023-2024 · 2025-2026 (this page).